Table 2.
Baseline Characteristics of 563 Febrile Neutropenia Episodes
| Febrile neutropenia characteristics | |
|---|---|
| Median (range) time of fever prior to admission (days) | 1 (0,60) |
| Interval since last chemotherapy (days) (Median, range) | 10 (0,148) |
| Laboratory results at the time of febrile neutropenia diagnosis– Median (range) | |
| Hemoglobin, g/dl | 9.5 (2.7-26) |
| White blood cell count, cells/mm3 | 670 (10-235,150) |
| Absolute neutrophil count, cells/mm3 | 70 (0-9,522) |
| Platelet, cells/mm3 | 79,092 (1,000-601,000) |
| Duration of fever in days (mean±SD) | 4.8±4.7 |
| Etiology of fever, n (%) | |
| Fever of unknown origin | 279 (49.6) |
| Microbiologically documented infection | 192 (34.1) |
| Clinically documented infection | 92 (16.3) |
| Type of pathogen, (n, %) | |
| Bacteria | 154 (27.3) |
| Virus | 32 (5.7) |
| Fungus | 27 (4.8) |
| Duration of neutropenia (days) (Median, range) | 8 (1,49) |
| Median (range) interval from last chemotherapy (days) | 10 (0-148) |
| Previous history of febrile neutropenia (n, %) | 337 (59) |
| Antifungal therapy in the past 6 months (n, %) | 123 (21.8) |
| G-CSF use (n, %) | 164 (29.1) |
| Steroid in the past 14 days (n, %) | 226 (40.1) |
| Central venous catheter (n, %) | 226 (40.1) |
| High risk in CPG (n, %) | 426 (75.7) |
| Follow CPG (n, %) | 373 (66) |
| Mortality within 2 weeks of febrile episode, (n, %) | 21 (3.7) |
G-CSF,Granulocyte colony stimulating factor